fda compounding semaglutide news october 2025 September 2, 2025: U.S. restrictions have stemmed a flood of compounded and tirzepatide – Partnership for Safe Medicines Important Update: Changes to Compounded

Behind the scenes the market leans on active pharmaceutical ingredients, peptide synthesis technologies, biologic manufacturing processes, and better drug delivery systems that keep the effect stable

Based on these results, semaglutide is expected to be submitted to FDA for MASH in 2025, potentially becoming the first GLP-1 RA officially approved for MASH

Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in an interview on Wednesday that the drugmaker is still frustrated that "mass marketing of a product unapproved by the FDA" is continuing, and said it was up to the U.S

While phentermine is a generic drug, it is also available under the brand names Adipex-P, Lomaira, Fastin, and others